NeuroSense Reports Statistically Significant 65% Reduction in ALS Death Risk with PrimeC in Phase 2b Trial
NRSN sits 49% above its 52-week low of $0.68.
Summary
NeuroSense Therapeutics announced new long-term survival data from its Phase 2b trial for PrimeC in ALS, showing a statistically significant 65% reduction in the risk of death and over 14 months median survival benefit.
Key Events · Product Development and Regulatory · NRSN
-
PrimeC Demonstrates Significant Survival Benefit
New long-term data from the PARADIGM Phase 2b trial showed PrimeC reduced the risk of death by 65% (p=0.0037) in ALS patients compared to placebo.
-
Extended Median Survival
Patients treated with PrimeC achieved an estimated median survival of 36.3 months, a 14-month (70%) improvement over the placebo group.
-
Strengthens Regulatory Position
These findings are expected to substantially strengthen the clinical and regulatory foundation for advancing PrimeC into pivotal late-stage development, building on the recent Australian patent grant for PrimeC on February 9, 2026.
Analysis · NRSN · Life Sciences
This filing provides highly positive and material clinical data for NeuroSense Therapeutics' lead drug candidate, PrimeC, in the treatment of Amyotrophic Lateral Sclerosis (ALS). The statistically significant 65% reduction in the risk of death and a 14-month increase in median survival are substantial outcomes for a devastating neurodegenerative disease with limited treatment options. This data significantly strengthens the clinical and regulatory profile of PrimeC, enhancing its potential for late-stage development and improving the company's position for future capital raises, especially following its recent universal shelf registration.
At the time of this filing, NRSN was trading at $1.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $29.7M. The 52-week trading range was $0.68 to $2.60. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.